Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.

Isamu Okamoto, Akinobu Hamada, Yusuke Matsunaga, Ji ichiro Sasaki, Shinji Fujii, Hideshi Uramoto, Haruhiko Yamagata, Ichiro Mori, Hiroto Kishi, Hiroshi Semba, Hideyuki Saito

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Amrubicin is a novel synthetic 9-aminoanthracycline derivative and is converted enzymatically to its C-13 hydroxy metabolite, amrubicinol, whose cytotoxic activity is 10-100 times that of amrubicin. We aimed to determine the maximum tolerated dose (MTD) of amrubicin and to characterize the pharmacokinetics of amrubicin and amrubicinol in previously treated patients with refractory or relapsed lung cancer. The 15 patients were treated with amrubicin intravenously at doses of 30, 35, or 40 mg/m(2) on three consecutive days every 3 weeks for a total of 43 courses. Neutropenia was the major toxicity (grade 4, 67%). The MTD was 40 mg/m(2), with the specific dose-limiting toxicities being grade 4 neutropenia persisting for >4 days, febrile neutropenia, or grade 3 arrhythmia in the three patients treated at this dose. A patient with non-small-cell lung cancer showed a partial response, and ten individuals experienced a stable disease. The area under the plasma concentration versus time curve (AUC) for amrubicin and that for amrubicinol increased with amrubicin dose. The amrubicin AUC was significantly correlated with the amrubicinol AUC. The recommended phase II dose of amrubicin for patients with lung cancer refractory to standard chemotherapy is thus 35 mg/m(2) once a day for three consecutive days every 3 weeks.

Original languageEnglish
Pages (from-to)282-288
Number of pages7
JournalCancer chemotherapy and pharmacology
Volume57
Issue number3
DOIs
Publication statusPublished - Jan 1 2006
Externally publishedYes

Fingerprint

Pharmacokinetics
Refractory materials
Lung Neoplasms
Area Under Curve
Maximum Tolerated Dose
Neutropenia
Toxicity
amrubicin
Febrile Neutropenia
Chemotherapy
Metabolites
Non-Small Cell Lung Carcinoma
Cardiac Arrhythmias
Cells
Derivatives
Plasmas
Drug Therapy
amrubicinol

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. / Okamoto, Isamu; Hamada, Akinobu; Matsunaga, Yusuke; Sasaki, Ji ichiro; Fujii, Shinji; Uramoto, Hideshi; Yamagata, Haruhiko; Mori, Ichiro; Kishi, Hiroto; Semba, Hiroshi; Saito, Hideyuki.

In: Cancer chemotherapy and pharmacology, Vol. 57, No. 3, 01.01.2006, p. 282-288.

Research output: Contribution to journalArticle

Okamoto, I, Hamada, A, Matsunaga, Y, Sasaki, JI, Fujii, S, Uramoto, H, Yamagata, H, Mori, I, Kishi, H, Semba, H & Saito, H 2006, 'Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.', Cancer chemotherapy and pharmacology, vol. 57, no. 3, pp. 282-288. https://doi.org/10.1007/s00280-005-0051-2
Okamoto, Isamu ; Hamada, Akinobu ; Matsunaga, Yusuke ; Sasaki, Ji ichiro ; Fujii, Shinji ; Uramoto, Hideshi ; Yamagata, Haruhiko ; Mori, Ichiro ; Kishi, Hiroto ; Semba, Hiroshi ; Saito, Hideyuki. / Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. In: Cancer chemotherapy and pharmacology. 2006 ; Vol. 57, No. 3. pp. 282-288.
@article{0f5fe5b38bdc480f99757641714b9402,
title = "Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.",
abstract = "Amrubicin is a novel synthetic 9-aminoanthracycline derivative and is converted enzymatically to its C-13 hydroxy metabolite, amrubicinol, whose cytotoxic activity is 10-100 times that of amrubicin. We aimed to determine the maximum tolerated dose (MTD) of amrubicin and to characterize the pharmacokinetics of amrubicin and amrubicinol in previously treated patients with refractory or relapsed lung cancer. The 15 patients were treated with amrubicin intravenously at doses of 30, 35, or 40 mg/m(2) on three consecutive days every 3 weeks for a total of 43 courses. Neutropenia was the major toxicity (grade 4, 67{\%}). The MTD was 40 mg/m(2), with the specific dose-limiting toxicities being grade 4 neutropenia persisting for >4 days, febrile neutropenia, or grade 3 arrhythmia in the three patients treated at this dose. A patient with non-small-cell lung cancer showed a partial response, and ten individuals experienced a stable disease. The area under the plasma concentration versus time curve (AUC) for amrubicin and that for amrubicinol increased with amrubicin dose. The amrubicin AUC was significantly correlated with the amrubicinol AUC. The recommended phase II dose of amrubicin for patients with lung cancer refractory to standard chemotherapy is thus 35 mg/m(2) once a day for three consecutive days every 3 weeks.",
author = "Isamu Okamoto and Akinobu Hamada and Yusuke Matsunaga and Sasaki, {Ji ichiro} and Shinji Fujii and Hideshi Uramoto and Haruhiko Yamagata and Ichiro Mori and Hiroto Kishi and Hiroshi Semba and Hideyuki Saito",
year = "2006",
month = "1",
day = "1",
doi = "10.1007/s00280-005-0051-2",
language = "English",
volume = "57",
pages = "282--288",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.

AU - Okamoto, Isamu

AU - Hamada, Akinobu

AU - Matsunaga, Yusuke

AU - Sasaki, Ji ichiro

AU - Fujii, Shinji

AU - Uramoto, Hideshi

AU - Yamagata, Haruhiko

AU - Mori, Ichiro

AU - Kishi, Hiroto

AU - Semba, Hiroshi

AU - Saito, Hideyuki

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Amrubicin is a novel synthetic 9-aminoanthracycline derivative and is converted enzymatically to its C-13 hydroxy metabolite, amrubicinol, whose cytotoxic activity is 10-100 times that of amrubicin. We aimed to determine the maximum tolerated dose (MTD) of amrubicin and to characterize the pharmacokinetics of amrubicin and amrubicinol in previously treated patients with refractory or relapsed lung cancer. The 15 patients were treated with amrubicin intravenously at doses of 30, 35, or 40 mg/m(2) on three consecutive days every 3 weeks for a total of 43 courses. Neutropenia was the major toxicity (grade 4, 67%). The MTD was 40 mg/m(2), with the specific dose-limiting toxicities being grade 4 neutropenia persisting for >4 days, febrile neutropenia, or grade 3 arrhythmia in the three patients treated at this dose. A patient with non-small-cell lung cancer showed a partial response, and ten individuals experienced a stable disease. The area under the plasma concentration versus time curve (AUC) for amrubicin and that for amrubicinol increased with amrubicin dose. The amrubicin AUC was significantly correlated with the amrubicinol AUC. The recommended phase II dose of amrubicin for patients with lung cancer refractory to standard chemotherapy is thus 35 mg/m(2) once a day for three consecutive days every 3 weeks.

AB - Amrubicin is a novel synthetic 9-aminoanthracycline derivative and is converted enzymatically to its C-13 hydroxy metabolite, amrubicinol, whose cytotoxic activity is 10-100 times that of amrubicin. We aimed to determine the maximum tolerated dose (MTD) of amrubicin and to characterize the pharmacokinetics of amrubicin and amrubicinol in previously treated patients with refractory or relapsed lung cancer. The 15 patients were treated with amrubicin intravenously at doses of 30, 35, or 40 mg/m(2) on three consecutive days every 3 weeks for a total of 43 courses. Neutropenia was the major toxicity (grade 4, 67%). The MTD was 40 mg/m(2), with the specific dose-limiting toxicities being grade 4 neutropenia persisting for >4 days, febrile neutropenia, or grade 3 arrhythmia in the three patients treated at this dose. A patient with non-small-cell lung cancer showed a partial response, and ten individuals experienced a stable disease. The area under the plasma concentration versus time curve (AUC) for amrubicin and that for amrubicinol increased with amrubicin dose. The amrubicin AUC was significantly correlated with the amrubicinol AUC. The recommended phase II dose of amrubicin for patients with lung cancer refractory to standard chemotherapy is thus 35 mg/m(2) once a day for three consecutive days every 3 weeks.

UR - http://www.scopus.com/inward/record.url?scp=33644838068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644838068&partnerID=8YFLogxK

U2 - 10.1007/s00280-005-0051-2

DO - 10.1007/s00280-005-0051-2

M3 - Article

C2 - 16028099

AN - SCOPUS:33644838068

VL - 57

SP - 282

EP - 288

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -